- Home
- LARK vs AVTX Comparison
LARK vs AVTX Comparison
Compare LARK & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LARK
- AVTX
- Stock Information
- Founded
- LARK 1885
- AVTX 2011
- Country
- LARK United States
- AVTX United States
- Employees
- LARK N/A
- AVTX N/A
- Industry
- LARK Major Banks
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- LARK Finance
- AVTX Health Care
- Exchange
- LARK Nasdaq
- AVTX Nasdaq
- Market Cap
- LARK 142.3M
- AVTX 118.6M
- IPO Year
- LARK N/A
- AVTX 2015
- Fundamental
- Price
- LARK $26.83
- AVTX $9.88
- Analyst Decision
- LARK
- AVTX Strong Buy
- Analyst Count
- LARK 0
- AVTX 8
- Target Price
- LARK N/A
- AVTX $31.00
- AVG Volume (30 Days)
- LARK 6.7K
- AVTX 335.9K
- Earning Date
- LARK 07-24-2025
- AVTX 08-07-2025
- Dividend Yield
- LARK 3.26%
- AVTX N/A
- EPS Growth
- LARK 43.23
- AVTX N/A
- EPS
- LARK 2.81
- AVTX N/A
- Revenue
- LARK $62,413,000.00
- AVTX $441,000.00
- Revenue This Year
- LARK N/A
- AVTX N/A
- Revenue Next Year
- LARK N/A
- AVTX N/A
- P/E Ratio
- LARK $9.18
- AVTX N/A
- Revenue Growth
- LARK 11.63
- AVTX N/A
- 52 Week Low
- LARK $18.81
- AVTX $3.39
- 52 Week High
- LARK $31.04
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- LARK 57.33
- AVTX 76.24
- Support Level
- LARK $25.75
- AVTX $8.41
- Resistance Level
- LARK $26.86
- AVTX $9.80
- Average True Range (ATR)
- LARK 0.73
- AVTX 0.85
- MACD
- LARK 0.18
- AVTX -0.01
- Stochastic Oscillator
- LARK 88.23
- AVTX 87.52
About LARK Landmark Bancorp Inc.
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).